The recently announced sale of Alere Inc.'s (ALR) Triage assets isn't the only divestiture in connection with Abbott Laboratories' (ABT) acquisition of Alere.

Abbott Chairman and CEO Miles White said on an earnings call Thursday that there is one more asset sale the company will make to secure regulatory approval for the Abbott-Alere deal.

"We've got a good buyer, a good price," White said. "The other party just hasn't said anything publicly, so we don't want to say it if they haven't said it."

He expects details of the divestiture will be made public soon.

On Monday, Quidel Corp. (QDEL) announced a deal to buy the Triage MeterPro cardiovascular and toxicology assets and the B-type Naturietic Peptide assay business run on Beckman Coulter analyzers from Alere for $400 million plus $40 million in contingent consideration.

Abbott expects to complete its acquisition of Alere by the end of the third quarter.

In April, Abbott and Alere agreed to shave $500 million off the deal's price tag, ending litigation between the two companies. Under the amended agreement, Abbott will pay $51 per Alere share, or $5.3 billion in equity value. In their original merger agreement, announced Feb. 1, 2016, Abbott agreed to pay $56 per share, an equity value of $5.8 billion, with an enterprise value of $7.9 billion.  

On July 7, Alere said its shareholders have voted to approve the amended merger.

Abbott is a holding in Jim Cramer's Action Alerts PLUS Charitable Trust Portfolio. Want to be alerted before Cramer buys or sells ABT? Learn more
now.


Also on Thursday's call, White talked about Abbott's $33 billion acquisition of St. Jude Medical Inc., which was completed in January.

"The integration of St. Jude continues to go well and we're right on track with our deal model and projected synergy targets," White said.

Abbott reported second-quarter adjusted diluted earnings per share from continuing operations of 62 cents on revenue of $6.6 billion. Analysts have forecast adjusted EPS of 61 cents on revenue of $6.6 billion, according to Bloomberg.

The Abbott Park, Ill.-based company upped its full-year 2017 earnings per share guidance range. Abbott now expects diluted EPS from continuing operations under GAAP to be $1.03 to $1.13 from $0.92 to $1.02 previously. In addition, it now projects diluted EPS from continuing operations on an adjusted basis to be $2.43 to $2.53, compared with the previous guidance of $2.40 to $2.50.

Shares of Abbott were trading at $50.01 on Thursday, up 1.1%. Alere shares were trading at $50.46, up 0.2%.

Worried about how to finance your golden years? Register here to watch a free webinar in which TheStreet's Jim Cramer talks with Ken Fisher, founder of Fisher Investments, about the market trends shaping retirement planning today

More from Health

How to Invest in Cannabis - In Its Many Forms

How to Invest in Cannabis - In Its Many Forms

How to Get a Medical Marijuana Card

How to Get a Medical Marijuana Card

How To Get Rid of Fleas In Your House And More

How To Get Rid of Fleas In Your House And More

Sprout CEO: Don't Call Her Drug the Female Viagra

Sprout CEO: Don't Call Her Drug the Female Viagra

Can Legal Cannabis Help Slow the Opioid Drug Epidemic in the U.S.?

Can Legal Cannabis Help Slow the Opioid Drug Epidemic in the U.S.?